Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
145 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Allergic Asthma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Allergic Asthma - Pipeline Review, H2 2014', provides an overview of the Allergic Asthma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Asthma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Asthma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Asthma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Asthma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Allergic Asthma Overview 10 Therapeutics Development 11 Pipeline Products for Allergic Asthma - Overview 11 Pipeline Products for Allergic Asthma - Comparative Analysis 12 Allergic Asthma - Therapeutics under Development by Companies 13 Allergic Asthma - Therapeutics under Investigation by Universities/Institutes 16 Allergic Asthma - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Allergic Asthma - Products under Development by Companies 20 Allergic Asthma - Products under Investigation by Universities/Institutes 22 Allergic Asthma - Companies Involved in Therapeutics Development 23 AIM Therapeutics Inc. 23 ALK-Abello A/S 24 Allergopharma Joachim Ganzer KG 25 Array BioPharma Inc. 26 Aslan Pharmaceuticals Pte. Ltd. 27 Asmacure Ltee 28 BioTech Tools s.a. 29 Fountain Biopharma Inc. 30 Genentech, Inc. 31 Infinity Pharmaceuticals, Inc. 32 Kineta, Inc. 33 Marinomed Biotechnologie GmbH 34 NeoPharm Co., Ltd. 35 Novartis AG 36 Nuvo Research Inc. 37 Panacea Biotec Limited 38 Peptinnovate Limited 39 Pharmaxis Limited 40 Portola Pharmaceuticals, Inc. 41 Protectimmun GmbH 42 Pulmatrix, Inc. 43 Stallergenes S.A. 44 sterna biologicals Gmbh & Co KG 45 Verona Pharma Plc 46 Allergic Asthma - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Combination Products 48 Assessment by Target 49 Assessment by Mechanism of Action 51 Assessment by Route of Administration 53 Assessment by Molecule Type 55 Drug Profiles 57 (fluticasone propionate + salmeterol xinafoate) - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Acaroid - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Actair - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 AcTMP-1 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 AIM-102 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 allergenic pollen extract of timothy - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Arabinogalactan - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 ARRY-502 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 ASLAN-004 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 ASM-024 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 ASM-8 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 dalazatide - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Drug to Inhibit PI3 Kinase Delta for Asthma - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 duvelisib - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 E-3.56 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 FB-825 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 fevipiprant - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 hdm-ASIT - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Lactococcus lactis G121 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 MAM-06301 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 MK-8237 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 omalizumab biosimilar - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 omalizumab biosimilar - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 PIN-201601 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 PRT-2607 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 QGE-031 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 quilizumab - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 RPL-554 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 SB-010 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 SG-100 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Small Molecule for Allergic Asthma - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Small Molecule for Allergic Asthma - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Small Molecules for Allergic Asthma - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Small Molecules to Inhibit C-Rel for Central Nervous System, Immunology, Musculoskeletal, Oncology, Respiratory and Metabolic Disorders - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 Synthetic Peptide for Gastrointestinal, Respiratory and CNS Disorders - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 Timothy Grass Pollen Allergen Extract - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 Vaccine for Allergic Rhinitis and Allergic Asthama - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 WF-10 - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 WF-10 liposomal - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 Allergic Asthma - Recent Pipeline Updates 111 Allergic Asthma - Dormant Projects 134 Allergic Asthma - Discontinued Products 137 Allergic Asthma - Product Development Milestones 138 Featured News & Press Releases 138 Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 138 May 16, 2013: Asmacure Announces Presentation Of Four Posters On ASM-024 At ATS 2013 International Conference 139 May 14, 2013: Nuvo Research Secures US Patent For Treatment Of Allergic Rhinitis And Allergic Asthma With WF10 140 Apr 15, 2013: Asmacure Doses First Subjects With ASM-024 Dry Powder For Inhalation 140 Apr 08, 2013: S-TARget Achieves In Vivo Proof Of Concept For Its Allergy Vaccine SG100 141 Mar 27, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet 142 Apr 17, 2012: Pharmaxis Completes Phase II Clinical Study With ASM8 In Asthma Patients 142 Appendix 144 Methodology 144 Coverage 144 Secondary Research 144 Primary Research 144 Expert Panel Validation 144 Contact Us 145 Disclaimer 145
List of Tables Number of Products under Development for Allergic Asthma, H2 2014 11 Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2014 12 Number of Products under Development by Companies, H2 2014 14 Number of Products under Development by Companies, H2 2014 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H2 2014 16 Comparative Analysis by Late Stage Development, H2 2014 17 Comparative Analysis by Clinical Stage Development, H2 2014 18 Comparative Analysis by Early Stage Development, H2 2014 19 Products under Development by Companies, H2 2014 20 Products under Development by Companies, H2 2014 (Contd..1) 21 Products under Investigation by Universities/Institutes, H2 2014 22 Allergic Asthma - Pipeline by AIM Therapeutics Inc., H2 2014 23 Allergic Asthma - Pipeline by ALK-Abello A/S, H2 2014 24 Allergic Asthma - Pipeline by Allergopharma Joachim Ganzer KG, H2 2014 25 Allergic Asthma - Pipeline by Array BioPharma Inc., H2 2014 26 Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2014 27 Allergic Asthma - Pipeline by Asmacure Ltee, H2 2014 28 Allergic Asthma - Pipeline by BioTech Tools s.a., H2 2014 29 Allergic Asthma - Pipeline by Fountain Biopharma Inc., H2 2014 30 Allergic Asthma - Pipeline by Genentech, Inc., H2 2014 31 Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 32 Allergic Asthma - Pipeline by Kineta, Inc., H2 2014 33 Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H2 2014 34 Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H2 2014 35 Allergic Asthma - Pipeline by Novartis AG, H2 2014 36 Allergic Asthma - Pipeline by Nuvo Research Inc., H2 2014 37 Allergic Asthma - Pipeline by Panacea Biotec Limited, H2 2014 38 Allergic Asthma - Pipeline by Peptinnovate Limited, H2 2014 39 Allergic Asthma - Pipeline by Pharmaxis Limited, H2 2014 40 Allergic Asthma - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 41 Allergic Asthma - Pipeline by Protectimmun GmbH, H2 2014 42 Allergic Asthma - Pipeline by Pulmatrix, Inc., H2 2014 43 Allergic Asthma - Pipeline by Stallergenes S.A., H2 2014 44 Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H2 2014 45 Allergic Asthma - Pipeline by Verona Pharma Plc, H2 2014 46 Assessment by Monotherapy Products, H2 2014 47 Assessment by Combination Products, H2 2014 48 Number of Products by Stage and Target, H2 2014 50 Number of Products by Stage and Mechanism of Action, H2 2014 52 Number of Products by Stage and Route of Administration, H2 2014 54 Number of Products by Stage and Molecule Type, H2 2014 56 Allergic Asthma Therapeutics - Recent Pipeline Updates, H2 2014 111 Allergic Asthma - Dormant Projects, H2 2014 134 Allergic Asthma - Dormant Projects (Contd..1), H2 2014 135 Allergic Asthma - Dormant Projects (Contd..2), H2 2014 136 Allergic Asthma - Discontinued Products, H2 2014 137
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
